Pharmaceuticals, Biotechnology and Life Sciences
FDA and EMA regulatory review of VBI’s 3-antigen HBV vaccine candidate ongoing – U.S. PDUFA target action date November 30, 2021
Initiation of the first Phase 1/2 study of VBI-2902, VBI’s monovalent COVID-19 vaccine candidate, expected in Q1 2021, …
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today a fifth round of grants in its Merck for Mothers Global Grants program dedicated to reducing maternal mortality in locat…
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the H.C. Wainwright G…
Astronomy and Pathology (AstroPath™) come together for the first time to discover and clinically validate new spatial phenotypic signatures using multiplex immunofluorescence.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Akoya Biosciences, Inc., The Spatial B…
SAN FRANCISCO–(BUSINESS WIRE)–$SPRB #CAH–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announ…
SALT LAKE CITY–(BUSINESS WIRE)–PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright Global Life Sciences Virtual Conference held …
VANCOUVER, British Columbia–(BUSINESS WIRE)–ARTMS Inc., the global leader in the development and commercialization of novel technologies and products enabling cyclotron production of the world’s most needed medical radioisotopes, is pleased to announ…
The aim of the new website is to become a reference of rigorous and useful information on menopause, osteoporosis, fertility and contraception.
The new website contains up-to-date therapy area information for both HCPs and general public. The local…
Second half of 2021 remains the target for completion of enrollment of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML)
Enrollment in 2021 is expected to sup…
PDUFA Date Expected 4Q 2021
NEW YORK–(BUSINESS WIRE)–#mydriasis–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U.S. F…